Celgene
Part of Bristol Myers Squibb
CompanyUnited StatesFounded 1986
Celgene develops 4 assets, the furthest approved (lisocabtagene maraleucel in follicular lymphoma). Mostly protein or enzyme and cell therapy acting on CD19, TGFB2 and TGFB1; based in the United States, founded in 1986.
- 4
- Assets
- Furthest stage
- Approved
- 228
- Trials
- 31
- Signals
Pipeline
4Engineered CAR T cells recognize CD19 and kill CD19-expressing malignant B cells.
Approved, Cell therapy, CD19, follicular lymphoma, diffuse large B-cell lymphoma
Traps select TGF-beta superfamily ligands, reducing SMAD2/3 signaling to promote late-stage red blood cell maturation.
Approved, Protein or enzyme, TGFB2, TGFB1, anemia, beta thalassemia
Traps activin-family ligands to rebalance vascular signaling and reduce pulmonary vascular remodeling.
Approved, Protein or enzyme, INHBA, pulmonary arterial hypertension, pulmonary hypertension (Phase 3)
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms7
- Trials731
- Signals20
- Similar companies6